스텔라라(우스테키누맙) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Stelara (Ustekinumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,661,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,629,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,596,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

스텔라라(우스테키누맙) 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 스텔라라의 적응증 확대, 자가 면역 질환의 유병률 증가, 대체 약물에 비해 난치성 질환에 대한 높은 효능, 환자 및 의료 서비스 제공자의 인식 제고, 맞춤형 의약품에 대한 관심 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 생물학적 요법의 채택, 첨단 의약품 전달 시스템의 개발, 데이터 기반 의료 시스템, 제약 회사 간의 파트너십 및 라이선스 계약, 생물학적 제제 제조 기술의 발전 등이 있습니다.

건선의 유병률이 증가함에 따라 앞으로 스텔라라(우스테키누맙) 시장의 성장이 촉진될 것으로 예상됩니다. 건선 환자는 피부 세포의 재생을 촉진하여 붉은 비늘 모양의 반점이 생기는 만성 자가 면역 질환을 앓고 있는 사람들입니다. 건선 유병률의 증가는 진단 기술의 발전, 환경적 요인, 유전적 소인, 인구 고령화 등의 요인에 기인할 수 있습니다. 스텔라라(우스테키누맙)는 인터루킨-12와 인터루킨-23을 표적으로 억제하여 염증과 플라크 형성을 효과적으로 감소시켜 건선 환자에게 도움이 됩니다. 이는 피부 개선과 장기적인 증상 관리로 이어져 환자의 삶의 질을 향상시킵니다. 예를 들어, 2024년 5월 미국 국립 의학 도서관(National Library of Medicine)의 보고서에 따르면 2022년 건선 유병률은 0.221%로 증가했으며, 313만 3,500명의 인구 중 PsA(건선성 관절염) 환자는 6,930명으로 보고되었습니다. 이로 인해 건선 환자의 유병률 증가가 스텔라라(우스테키누맙) 시장 성장을 촉진할 것으로 예상됩니다.

스텔라라(우스테키누맙) 시장의 주요 동향은 만성 염증 질환 환자에게 비용 효율적인 치료 옵션을 제공하는 스텔라라 바이오시밀러와 같은 혁신적인 제품의 개발입니다. 스텔라라 바이오시밀러는 스텔라라(우스테키누맙)의 치료 효과를 복제하도록 설계된 생물학적 유사 의약품으로, IL-12 및 IL-23을 표적으로 하여 건선 및 건선 관절염과 같은 자가 면역 질환을 치료합니다. 예를 들어, 2024년 10월, 미국에 본사를 둔 바이오 제약 회사인 Accord BioPharma Inc.는 미국 식품의약국(FDA)이 Johnson & Johnson의 STELARA(우스테키누맙)의 바이오시밀러인 IMULDOSA(우스테키누맙-srlf)를 승인했다고 발표했습니다. IMULDOSA는 광범위한 적응증으로 주목받고 있으며, 중등도에서 중증의 판상 건선, 활동성 건선성 관절염, 중등도에서 중증의 크론병, 궤양성 대장염을 앓는 성인 환자에게 치료를 제공합니다. 또한 6세 이상 소아 환자의 중등도에서 중증의 판상 건선 및 활동성 건선성 관절염에 유일하게 적응증이 지정되어 다양한 연령층에서 활용 가능합니다. 이처럼 광범위한 적응증은 IMULDOSA를 다양한 면역매개 염증성 질환의 치료 옵션으로 가치 있는 약물로 자리매김하게 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 스텔라라(우스테키누맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 스텔라라(우스테키누맙) 시장 : 성장률 분석
• 세계의 스텔라라(우스테키누맙) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 스텔라라(우스테키누맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 스텔라라(우스테키누맙) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 스텔라라(우스테키누맙) 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 심상성 건선
• 건선성 관절염
• 크론병
• 궤양성 대장염
• 기타
• 세계의 스텔라라(우스테키누맙) 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 피하 주사
• 정맥내 주입
• 세계의 스텔라라(우스테키누맙) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 스텔라라(우스테키누맙) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아
• 성인
• 고령자

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 스텔라라(우스테키누맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 스텔라라(우스테키누맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 스텔라라(우스테키누맙) 시장 : 경쟁 구도
• 스텔라라(우스테키누맙) 시장 : 기업 프로파일
  • Johnson & Johnson

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 스텔라라(우스테키누맙) 시장(2029년) : 새로운 기회를 제공하는 국가
• 스텔라라(우스테키누맙) 시장(2029년) : 새로운 기회를 제공하는 부문
• 스텔라라(우스테키누맙) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two key proteins involved in inflammatory and autoimmune responses. It is commonly used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for stelara (Ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and other conditions. Plaque psoriasis is a chronic autoimmune disorder that leads to the rapid buildup of skin cells, creating scaly, inflamed patches, often on the scalp, elbows, and knees. Stelara can be administered via subcutaneous injection or intravenous infusion and is available through various distribution channels, including hospital, retail, and online pharmacies. It is used for pediatric, adult, and geriatric patients.

The stelara (ustekinumab) market research report is one of a series of new reports from The Business Research Company that provides stelara (ustekinumab) market statistics, including stelara (ustekinumab) industry global market size, regional shares, competitors with a stelara (ustekinumab) market share, detailed stelara (ustekinumab) market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. This stelara (ustekinumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $14,768.5 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to expanding indications for stelara, increasing prevalence of autoimmune diseases, high efficacy in refractory cases compared to alternatives, rising awareness among patients and healthcare providers, growing focus on personalized medicine. Major trends in the forecast period include adoption of biologic therapies, development of advanced drug delivery systems, data-driven healthcare systems, partnerships and licensing agreements between pharmaceutical companies, advances in biologics manufacturing technologies.

The growing prevalence of psoriasis is expected to drive the growth of the stelara (ustekinumab) market in the future. Psoriasis patients are individuals dealing with a chronic autoimmune disorder that speeds up skin cell turnover, resulting in red, scaly patches. The rise in psoriasis prevalence can be attributed to factors such as better diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, which helps psoriasis patients by effectively reducing inflammation and plaque formation. This leads to improved skin clearance and long-term symptom management, ultimately enhancing patients' quality of life. For instance, in May 2024, a report from the National Library of Medicine, a U.S.-based medical library, revealed that in 2022, psoriasis prevalence increased to 0.221%, with 6,930 cases of PsA reported in a population of 3,133,500. As a result, the rising prevalence of psoriasis patients is expected to fuel the growth of the stelara (ustekinumab) market.

A key trend in the stelara (ustekinumab) market is the development of innovative products, such as Stelara biosimilars, which offer a cost-effective treatment option for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications designed to replicate the therapeutic effects of Stelara (Ustekinumab), targeting IL-12 and IL-23 to treat autoimmune diseases like psoriasis and psoriatic arthritis. For example, in October 2024, Accord BioPharma Inc., a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab). IMULDOSA is notable for its broad indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. It is also uniquely indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it versatile across different age groups. This wide range of indications positions IMULDOSA as a valuable treatment for various immune-mediated inflammatory diseases.

In December 2023, Lotus Pharmaceutical, a Taiwan-based pharmaceutical company, partnered with Favorex Pte Ltd. to introduce a biosimilar of ustekinumab to the South Korean market. With this collaboration, Lotus Pharmaceutical aims to leverage Favorex Pte Ltd.'s expertise and market presence to bring a cost-effective biosimilar of ustekinumab to South Korea, addressing the demand for affordable biologic therapies while expanding its presence in the region's pharmaceutical sector. Favorex Pte Ltd. is a pharmaceutical company based in Singapore.

The Key player operating in the stelara (ustekinumab) market is Johnson & Johnson.

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stelara (ustekinumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the stelara (ustekinumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stelara (Ustekinumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stelara (ustekinumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for stelara (ustekinumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The stelara (ustekinumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By End User: Pediatric; Adult; Geriatric
• Companies Mentioned: Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Stelara (Ustekinumab) Market Characteristics

3. Stelara (Ustekinumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Stelara (Ustekinumab) Market Trends And Strategies

5. Stelara (Ustekinumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Stelara (Ustekinumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Stelara (Ustekinumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Stelara (Ustekinumab) Market Growth Rate Analysis
• 6.4. Global Stelara (Ustekinumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Stelara (Ustekinumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Stelara (Ustekinumab) Total Addressable Market (TAM)

7. Global Stelara (Ustekinumab) Market Pricing Analysis & Forecasts

8. Stelara (Ustekinumab) Market Segmentation

• 8.1. Global Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plaque Psoriasis
• Psoriatic Arthritis
• Crohn's Disease
• Ulcerative Colitis
• Other Indications
• 8.2. Global Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous Injection
• Intravenous Infusion
• 8.3. Global Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 8.4. Global Stelara (Ustekinumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric

9. Global Stelara (Ustekinumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Stelara (Ustekinumab) Market Regional And Country Analysis

• 10.1. Global Stelara (Ustekinumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Stelara (Ustekinumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Stelara (Ustekinumab) Market

• 11.1. Asia-Pacific Stelara (Ustekinumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Stelara (Ustekinumab) Market

• 12.1. China Stelara (Ustekinumab) Market Overview
• 12.2. China Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Stelara (Ustekinumab) Market

• 13.1. India Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Stelara (Ustekinumab) Market

• 14.1. Japan Stelara (Ustekinumab) Market Overview
• 14.2. Japan Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Stelara (Ustekinumab) Market

• 15.1. Australia Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Stelara (Ustekinumab) Market

• 16.1. South Korea Stelara (Ustekinumab) Market Overview
• 16.2. South Korea Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Stelara (Ustekinumab) Market

• 17.1. Western Europe Stelara (Ustekinumab) Market Overview
• 17.2. Western Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Stelara (Ustekinumab) Market

• 18.1. UK Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Stelara (Ustekinumab) Market

• 19.1. Germany Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Stelara (Ustekinumab) Market

• 20.1. France Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Stelara (Ustekinumab) Market

• 21.1. Eastern Europe Stelara (Ustekinumab) Market Overview
• 21.2. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Stelara (Ustekinumab) Market

• 22.1. North America Stelara (Ustekinumab) Market Overview
• 22.2. North America Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Stelara (Ustekinumab) Market

• 23.1. USA Stelara (Ustekinumab) Market Overview
• 23.2. USA Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Stelara (Ustekinumab) Market

• 24.1. Canada Stelara (Ustekinumab) Market Overview
• 24.2. Canada Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Stelara (Ustekinumab) Market

• 25.1. South America Stelara (Ustekinumab) Market Overview
• 25.2. South America Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Stelara (Ustekinumab) Market

• 26.1. Middle East Stelara (Ustekinumab) Market Overview
• 26.2. Middle East Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Stelara (Ustekinumab) Market

• 27.1. Africa Stelara (Ustekinumab) Market Overview
• 27.2. Africa Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Stelara (Ustekinumab) Market Competitive Landscape And Company Profiles

• 28.1. Stelara (Ustekinumab) Market Competitive Landscape
• 28.2. Stelara (Ustekinumab) Market Company Profiles
  • 28.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

29. Global Stelara (Ustekinumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Stelara (Ustekinumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Stelara (Ustekinumab) Market

32. Recent Developments In The Stelara (Ustekinumab) Market

33. Stelara (Ustekinumab) Market High Potential Countries, Segments and Strategies

• 33.1 Stelara (Ustekinumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Stelara (Ustekinumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Stelara (Ustekinumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료